Novo Nordisk’s experimental heart drug Ziltivekimab missed key trial goals, eroding investor confidence in its growth beyond weight-loss treatments.
Novo Nordisk (NVO) shares plunged as much as 8.6% after its experimental heart drug Ziltivekimab failed the primary endpoint of the late-stage ZEUS trial. The Danish drugmaker’s U.S.-listed stock fell sharply in early trading, reflecting investor disappointment over the setback.
The ZEUS trial involved over 6,300 patients with cardiovascular disease, chronic kidney disease, and inflammation. Ziltivekimab was seen as a potential second growth driver alongside Novo’s blockbuster weight-loss and diabetes drugs, Wegovy and Ozempic.
The failure underscores the market’s reliance on Novo’s ability to diversify beyond its dominant obesity and diabetes franchises. Shares had rallied on hopes for Ziltivekimab’s success, making the trial’s outcome a critical test for the company’s long-term strategy.